Cytiva Partners with San Raffaele Institute to Advance Hematopoietic Stem Cell Gene Therapies
核心洞察
Cytiva (搜索) has launched a multi-year research collaboration with San Raffaele Telethon Institute for Gene Therapy (搜索) (SRTIGET (搜索)) to advance next-generation genomic medicine platforms, focusing on lentiviral gene transfer (搜索) and targeted gene editing of hematopoietic stem cells.
The partnership represents the first Danaher (搜索) Beacon in the European Union and aims to address persistent bottlenecks in cell and gene therapy (搜索) manufacturing, targeting high-impact areas where improvements can accelerate translation from discovery to delivery.
With 2,130 cell and gene therapy (搜索) clinical trials in progress in 2025, the collaboration seeks to optimize processes, improve consistency, reduce costs, and enhance scalability for genomic medicine platforms.
Cytiva (搜索), a Danaher (搜索) company, has announced a strategic research partnership with the San Raffaele Telethon Institute for Gene Therapy (搜索) (SRTIGET (搜索)) to advance next-generation genomic medicine platforms, with a specific focus on lentiviral gene transfer (搜索) and targeted gene editing of hematopoietic stem cells. The collaboration marks the first Danaher Beacon established in the European Union.
Strategic Focus on Hematopoietic Stem Cell Therapies
The partnership will prioritize optimization of lentiviral vector production and advancement of homology-directed repair-based gene editing in hematopoietic stem cells, with particular emphasis on automation of cell manipulation and process improvement. SRTIGET (搜索) brings significant expertise to the collaboration, having advanced gene therapies based on hematopoietic stem cells for more than two decades.
"For more than two decades, we have advanced gene therapies based on hematopoietic stem cells. Today SR-TIGET is recognized as a global leader in the field with the number of patients treated and diseases addressed, as well as of products approved for the EU and/or US market," said Professor Luigi Naldini, MD, PhD and Director of SR-TIGET. "More importantly, these treatments have been safe and truly transformative for our patients."
Addressing Manufacturing Bottlenecks
The initiative aims to tackle persistent bottlenecks in cell and gene therapy (搜索) manufacturing as the field experiences rapid growth. With 2,130 clinical trials in progress in 2025 alone, developers face increasing pressure to optimize processes, improve consistency, reduce costs, and accelerate timelines.
The collaboration will combine SRTIGET (搜索)'s scientific leadership with Cytiva (搜索)'s manufacturing expertise, spanning process development through commercialization. Additional partnership support will come from two other Danaher (搜索) companies: Aldevron (搜索) and Integrated DNA Technologies (搜索) (IDT).
Institutional Background and Market Impact
SRTIGET (搜索) operates as a joint venture between Ospedale San Raffaele (搜索) and Fondazione Telethon, an Italian non-profit organization committed to advancing research for rare genetic diseases (搜索). Notably, Fondazione Telethon recently became the first non-profit to bring a gene therapy (搜索) to market in the United States.
"The next challenge is to ensure that the new therapies that we are developing together with Fondazione Telethon can be brought to clinical testing and delivered to patients in a more robust, scalable, and economically sustainable way than is currently possible," Naldini explained.
Long-term Strategic Vision
Daria Donati, Chief Scientific Officer for Genomic Medicine at Cytiva (搜索), emphasized the collaboration's broader objectives: "Together, Danaher (搜索) and SR-TIGET share a clear ambition: to accelerate the translation of promising genomic technologies into therapies that can be delivered reliably, reproducibly, and at scale. The Beacon reflects a long-term commitment to building the foundational platforms required for genomic medicine to fulfill its promise—not just in pioneering trials, but for patients worldwide."
The partnership will extend for several years as part of Cytiva (搜索)'s broader effort to strengthen its genomic medicine portfolio and support innovators across the biotech ecosystem. The initiative seeks to enhance access to innovative tools for translational researchers aiming to implement promising genomic technologies more quickly and reliably, targeting high-impact areas where even small gains can meaningfully accelerate the transition from discovery to delivery.